INDOCO : ANACIPHER GETS ANVISA BRAZIL APPROVAL FOR CLINICAL AND BIOANALYTICAL FACILITIES

• AnaCipher, Indoco Remedies' clinical research organisation, approved by Brazil's ANVISA for clinical and bioanalytical facilities • Inspection was conducted from March 30, 2026, to April 7, 2026 • CRO now authorised to conduct bioavailability and bioequivalence studies for submission to Brazil, with associated bioanalytical support • AnaCipher already accredited by CDSCO, USFDA, WHO, EMA, UKMHRA and MoH-Oman; project-based approvals from TPD-Canada, NMPA-China, MCC-South Africa, MoH-Iraq • MD Aditi Panandikar said the approval reflects robust quality systems and enhances ability to support pharma companies for Brazil and Latin America • AnaCipher is headquartered in Hyderabad and provides bioequivalence, bioanalysis, clinical operations and regulatory services globally

Indoco Remedies Ltd

Open attachment

← Back to feed